Brain Circuits in Schizophrenia and Smoking
The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population. The investigators hope that the study will provide concrete biomarkers for new therapeutic development and ultimately reducing the smoking related health burden.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Brain Circuits in Schizophrenia and Smoking|
- Nicotine addiction severity is associated with abnormal functional connectivity as measured by fMRI,compared with nonsmokers.Schizophrenia pts are assoc with add'l functional connectivity impairment compared with controls [ Time Frame: 12-15 hours ] [ Designated as safety issue: No ]
- Symptom and Cognition rating [ Time Frame: 1-2 hours ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
- Whole Blood
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||January 2020|
|Estimated Primary Completion Date:||January 2020 (Final data collection date for primary outcome measure)|
smokers and nonsmokers
smokers and nonsmokers
There are several studies and hypotheses to be tested. This project includes (1) a cross-sectional study design that measures brain imaging, smoking, clinical diagnosis and symptoms, cognitive functional assessments, distress tolerance, and genetic information, which is also the baseline for the longitudinal study; and (2) a longitudinal study design for smoking cessation option for 1 year in some smokers and a longitudinal follow-up for all available subjects.
During the baseline portion of the study, subjects are expected to complete clinical symptom assessments, a computer challenge task to measure distress tolerance, MRI scan, role-play test to measure cognitive and functional abilities, and blood draw. Subjects who are eligible will participate in the longitudinal follow-up study where the research team will call subjects regularly regarding smoking related information (smoking risk and treatment options).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01425684
|Contact: L.Elliot Hong, M.D.||email@example.com|
|United States, Maryland|
|Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine||Recruiting|
|Baltimore, Maryland, United States, 21228|
|Contact: Kavita Thangavelu, MSW 410-402-6124 Kthangavelu@mprc.umaryland.edu|
|Principal Investigator:||L.Elliot Hong, M.D.||Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine|